Abstract

Given the rise in drug-resistant Streptococcus pneumoniae, there is an urgent need to discover new antimicrobials targeting this pathogen and an equally urgent need to characterize new drug targets. A promising antibiotic target is dihydrodipicolinate synthase (DHDPS), which catalyzes the rate-limiting step in lysine biosynthesis. In this study, we firstly show by gene knock out studies that S. pneumoniae (sp) lacking the DHDPS gene is unable to grow unless supplemented with lysine-rich media. We subsequently set out to characterize the structure, function and stability of the enzyme drug target. Our studies show that sp-DHDPS is folded and active with a k cat = 22 s-1, K M PYR = 2.55 ± 0.05 mM and K M ASA = 0.044 ± 0.003 mM. Thermal denaturation experiments demonstrate sp-DHDPS exhibits an apparent melting temperature (T M app) of 72 °C, which is significantly greater than Escherichia coli DHDPS (Ec-DHDPS) (T M app = 59 °C). Sedimentation studies show that sp-DHDPS exists in a dimer-tetramer equilibrium with a K D 4→2 = 1.7 nM, which is considerably tighter than its E. coli ortholog (K D 4→2 = 76 nM). To further characterize the structure of the enzyme and probe its enhanced stability, we solved the high resolution (1.9 Å) crystal structure of sp-DHDPS (PDB ID 3VFL). The enzyme is tetrameric in the crystal state, consistent with biophysical measurements in solution. Although the sp-DHDPS and Ec-DHDPS active sites are almost identical, the tetramerization interface of the s. pneumoniae enzyme is significantly different in composition and has greater buried surface area (800 Å2) compared to its E. coli counterpart (500 Å2). This larger interface area is consistent with our solution studies demonstrating that sp-DHDPS is considerably more thermally and thermodynamically stable than Ec-DHDPS. Our study describe for the first time the knock-out phenotype, solution properties, stability and crystal structure of DHDPS from S. pneumoniae, a promising antimicrobial target.

Highlights

  • Streptococcus pneumoniae is a Gram-positive bacterium and human commensal inhabiting the upper respiratory tract [1]

  • This demonstrates that the dapA gene, encoding dihydrodipicolinate synthase (DHDPS), is essential for the growth of S. pneumoniae in the absence of lysine

  • Current treatment relies primarily upon the use of penicillin-based antibiotics. This approach has had significant limitations given the emergence of drug-resistant S. pneumoniae (DRSP)

Read more

Summary

Introduction

Streptococcus pneumoniae is a Gram-positive bacterium and human commensal inhabiting the upper respiratory tract [1]. The organism often causes pneumonia in children, the elderly and immunocompromized, and if left untreated can result in death [2]. In recent years S. pneumoniae has received considerable attention due to the emergence of multi-drug resistant strains, commonly referred to as drug-resistant Streptococcus pneumoniae (DRSP) [3,4]. Becoming less effective due to the rise in DRSP [4,5,6,7]. This is in part due to the promiscuous nature of S. pneumoniae in acquiring genetic resistance elements from other bacteria, accompanied by selective pressure as a result of high antibiotic usage [8,9]. There is an urgent need to discover new therapeutics targeting appropriate biomolecules from S. pneumoniae

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call